Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Nicotinamide Adenine Dinucleotide

Phase 2

BBeijing Children's Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cardiac DysfunctionNot yet recruiting

Cardiac DysfunctionPhase 2

Not yet recruiting

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Cardiac Dysfunction

NCT07839130

Clinical

Trials by Indication[1]

Cardiac Dysfunction1 trial

The PEDI-NAD Trial: Injectable Nicotinamide Adenine Dinucleotide (NAD⁺) for Pediatric Cardiac Dysfunction: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Protocol

Not yet recruiting·BBeijing Children's Hospital·Phase 2·NCT07839130·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nicotinamide Adenine Dinucleotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Nicotinamide Adenine Dinucleotide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Beijing Children's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: BBeijing Children's Hospital

Related News